Daiichi Sankyo Company, Limited

Sankyo Company, Limited

Snow Brand Milk Products Co., Ltd.

Daiichi Pharmaceutical Co., Ltd.

Eisuke Tsuda

Kanji Higashio

Masaaki Goto

Fumie Kobayashi

Kazuki Yano

Nobuyuki Shima

Tomonori Morinaga

Hisataka Yasuda

Nobuaki Nakagawa

Yoshiharu Hiruma

Masatsugu Ueda

Kyoji Yamaguchi

Naohiro Washida

Shin'ichi Mochizuki

Masahiko Kinosaki

Akihiro Tomoyasu

Takeshi Takizawa

Makiko Nakayama

Ken Takahashi

Fumiko Oogaki

Yoshiji Yamada

Tohru Takahashi

Toshinori Agatsuma

Toshiaki Ohtsuka

Tatsuji Matsuoka

Ichiro Watanabe

Ingrid Schuster

Hiroaki Masunaga

Akihiko Murakami

Masaya Nagao

Dirk Ponsel

Sandra Miller

Ulrike Schubert

Hiroaki Takaoka

Shin-ichi Mochizuki

Tadashi Nakakarumai

Shin′ichi Mochizuki

Kaoji Higashio

Shinichi Mochizuki

Nobuaki Fujise

Chiharu Masuyama

Toshiko Satake

Reiko Takahira

Robert Mühlbacher

Kathrin-Ladetzki Baehs

Steffen Runz

Maikiko Nakayama

Takeschi Takizawa

To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like.

Antibody targeting osteoclast-related protein siglec-15

Antibody targeting osteoclast-related protein Siglec-15

Provided is a pharmaceutical composition for treating and/or preventing abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like.

Anti-Siglec-15 antibody

An isolated antibody capable of binding Siglec-15 which inhibits osteoclast formation and/or osteoclastic bone resorption, or a functional fragment thereof. The heavy chain of the antibody comprises a CDRH1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 106, a CDRH2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 107, and a CDRH3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 35, 45, 55, 65 or 80. The light chain of the antibody comprises a CDRL1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 73 or 83, a CDRL2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 108, and a CDRL3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 40, 50, 60, 70, 90, 100 or 109.

Methods of administering anti-Siglec-15 antibody

Novel proteins and polypeptides binding to osteoclastogenesis inhibitory factor (OCIF) (OCIF-binding molecules, OBMs) and nucleic acids encoding these proteins and polypeptides are provided. Processes for producing these proteins, polypeptides, and nucleic acid molecules by genetic engineering are provided. Medicinal compounds are provided which comprise proteins and nucleic acids according to the invention, as well as proteins which bind to OBM, including anti-OBM antibodies. These compounds may be used for the treatment of bone disease.

Methods of reducing bone absorption comprising administering an antibody that binds OBM

A protein which inhibits osteoclast differentiation and/or maturation and a method for producing the protein. The protein is produced by human embryonic lung fibroblasts and has a molecular weight of about 60 kD and about 120 kD under non-reducing conditions and about 60 kD under reducing conditions on SDS-polyacrylamide gel electrophoresis. The protein can be isolated and purified from the culture medium of fibroblasts. Furthermore, the protein can be produced by gene engineering. The present invention includes cDNA for producing the protein by gene engineering, antibodies having specific affinity for the protein or a method for determining protein concentration using these antibodies.

Nucleic acid molecules encoding osteoclastogenesis inhibitory factor proteins

The present invention relates to a novel protein which binds to Osteoclastogenesis Inhibitory Factor (OCIF-binding molecule; OBM), a process for preparing the same, DNA encoding said protein, a protein having an amino acid sequence encoded by this DNA, a method for producing said protein by genetic engineering technique, and a pharmaceutical composition containing said protein. In addition, screening methods for a substance for controlling expression of said protein using said protein and the DNA, a substance which inhibits or modulates the biological activity of said protein, or a receptor which transmits the action of said protein through binding to said protein, the substance obtained by the screening methods, and a pharmaceutical composition which contains this substance are disclosed. An antibody for said protein, a process for preparing the same, a measuring method of said protein using the antibody, and a medicine comprising the antibody are also disclosed.

Antibodies to OCIF-binding molecules

A protein which inhibits osteoclast differentiation and/or maturation and a method of production of the protein. The protein is produced by human embryonic lung fibroblasts and has molecular weight of about 60 kD and about 120 kD under non-reducing conditions and about 60 kD under reducing conditions on SDS-polyacrylamide gel electrophoresis, respectively. The protein can be isolated and purified from culture medium of the said fibroblasts. Furthermore, the protein can be produced by gene engineering. The present invention includes cDNA for producing the protein by gene engineering, antibodies having specific affinity to the protein or a method for determination of the protein concentration using the antibodies.

Methods for using the osteoclastogenesis inhibitory factor (OCIF) protein

A novel protein and a process of producing the protein is provided. The protein is a glycoprotein having activity of suppressing the differentiation and/or maturation of adipocyte, having a molecular weight of about 45 kD under non-reducing conditions and about 28 kD and/or 23 kD under reducing conditions, and exhibiting affinity to heparin. A process of producing the protein comprising culturing human fibroblasts and purifying the culture broth by chromatography using an ion exchange column, affinity column, and reverse phase column. A cDNA encoding the protein and a process of producing the protein using the cDNA are also provided. The protein of the present invention is useful as a pharmaceutical composition for preventing or treating obesity or as an antigen for establishing immunological diagnosis, etc.

Protein and processes for producing the same

Proteins and methods for producing the proteins

Growing community of inventors

Tochigi, Japan

Eisuke Tsuda